Top-Foren
|
|
|
---|---|---|
Gesamt | 85 | 1671 |
Börse | 29 | 974 |
Talk | 47 | 522 |
Blockchain | 8 | 194 |
Hot-Stocks | 9 | 175 |
Devisen | 8 | 50 |
Neue GPC entdeckt!
Seite 1 von 2
neuester Beitrag: 09.03.22 13:15
|
||||
eröffnet am: | 24.03.04 19:36 von: | geldschneide. | Anzahl Beiträge: | 26 |
neuester Beitrag: | 09.03.22 13:15 von: | Balu4u | Leser gesamt: | 8663 |
davon Heute: | 7 | |||
bewertet mit 0 Sternen |
||||
|
--button_text--
interessant
|
witzig
|
gut analysiert
|
informativ
|
0
Umsatz GPC 29,73 Mio 18,73
Ebitda -26,61 MIO - 2,00
Nettoverm.
je Aktie 1,38 2,17
Na, klingts nicht gut?
Kurs ca. bei 10 Euro!
In Deutschland noch nicht endeckt!
Dafür umso regerer Handel in USA
Ist aber kein USA Wert!
Wenn das nicht gut klingT!
GPC hat in USA sich noch nicht durchgesetzt!
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0 Postings ausgeblendet.
0
thx
Optionen
Antwort einfügen |
Boardmail an "FXTH" |
Wertpapier:
Transgene
|
0
Morgen lüfte ich das Geheimnis!
Viel mir auf, weil starker Kursanstieg!
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
tolle sache ... trotzdem viel glück ..
Optionen
Antwort einfügen |
Boardmail an "FXTH" |
Wertpapier:
Transgene
|
0
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
habe ich in eienm Anlegermagazin gelesen! Auch im Europ. Ausland.!
Leider findet man unter den US Seiten mehr über diesen Wert als in Deutsch!
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
die Aktie ist charttechnisch, kurz, mittel und lanfristig absolut zu 100 % auf Buy eingestellt!
Rein techn. eine Kaufempfehlung!
Es gibt kaum noch Werte mit diesem Kriterium, die nicht IT Werte bzw. Tech Werte sind!
Dieser Wert ein Biotech Wert, ist vom Kurs noch nicht so aufgeblasen wie GPC, außerdem hat der WErt bei den letzen Zahlen weniger Verluste ausgewiesen als im Vorjahr!
Amerik. Kürzel ist:TRGNY
Dies ist der ADR Wert 1/3, also nicht wundern!
good trades
geldschneider
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
La thérapie génique consiste à insérer dans les cellules du patient, au moyen de gènes ou de vecteurs, des instructions génétiques pour la production de protéines thérapeutiques.
Transgene a d'ores et déjà développé 7 familles de vecteurs qu'il utilise dans les domaines de la cancérologie (cancer du poumon, cancer du sein, cancer du col de l'utérus, cancer de la prostate, etc.) et des maladies héréditaires (myopathie et mucoviscidose).
Le portefeuille de produits du groupe se compose de la façon suivante : 5 produits destinés au traitement du cancer à différents stades de développement et 1 produit de thérapie génique contre la myopathie en évaluations cliniques. www.transgene.fr
hier auch auf englisch http://www.transgene.fr/us/?chapter=investor_relations
besonders interessant die Pipeline (man vergleiche mit GPC Biotech) http://www.transgene.fr/us/?chapter=product_pipeline
interessantes Mittel gegen häufige Unterleibs-Erkrankung in Phase 2 erfolgreich
http://www.bourse-de-paris.fr/nm/fr/pdf/...-03-2004%20MVA-HPV-IL2.pdf
der letzte Report v.11.2.war verbesserungsfähig
http://www.bourse-de-paris.fr/nm/fr/pdf/...%20financial%20results.pdf
besonders interessant scheinen die bisherigen Forschungsergebnisse zu einer Lungenkrebsimpfung in Phase 2 (zusammen mit Chemotherapie und Widerstandskraftverbesserung,wenn ich das richtig habe)
http://www.bourse-de-paris.fr/nm/fr/pdf/...9-02-2004%20MVA%20MUC1.pdf
bessere Infos noch unter http://www.bourse-de-paris.fr/fr/index_fs.htm?nc=2&ni=8&nom=marche ganz unten mit Jahreschart etc
hat mich einfach interessiert,weil kaum jemand in Frankreich investiert ist
Optionen
Antwort einfügen |
Boardmail an "Kicky" |
Wertpapier:
Transgene
|
0
Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated
to the discovery and development of therapeutic vaccines, immunotherapy
products, and delivery technologies for the treatment of diseases for which
there is no cure or adequate treatment at present, with a focus on the treatment
of cancer. Transgene has five products in clinical development, two of which are
in Phase II clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus.
This press release contains forward-looking statements, including statements
regarding the efficacy and safety of and potential market for Transgene's
product candidates and prospects. Statements that are not historical facts are
based on Transgene's current expectations, beliefs, estimates, forecasts and
assumptions, including Transgene's expectations related to progress in the
clinical trials and Transgene's belief as to the potential of MVA-HPV-IL2 as a
treatment for HPV-related diseases. The statements contained in this release are
not guarantees of future performance and involve certain risks, uncertainties
and assumptions which are difficult to predict. Accordingly, actual outcomes and
results may differ materially from what is expressed in those forward-looking
statements. Important factors which may affect Transgene's future operating
results include the following: Transgene's product candidates may not
demonstrate therapeutic efficacy after initial promising results, Transgene may
be unable to obtain regulatory approval for its product candidates, Transgene
may be unable to conduct its clinical trials as quickly as it has predicted,
Transgene's clinical trials may not produce results sufficient to justify
further product development, Transgene may not have sufficient resources to
complete the research and commercialization of any of its product candidates,
competitors may develop technologies or products superior to Transgene's
technologies or products, Transgene may not be able to successfully enforce the
intellectual property rights in all jurisdictions relating to its product
candidates and other important factors described in Transgene's Annual Report on
Form 20-F for the year ended December 31, 2002 filed with the U.S. Securities
and Exchange Commission, including those factors described in the section
entitled "Risk Factors."
SOURCE Transgene
CONTACT: Patrick Squiban, MD, VP Medical & Regulatory Affairs of
Transgene, +33-3-88-27-91-73; or Michael Long of Cohn & Wolfe,
+1-212-798-9775, for Transgene; or Estelle Guillot-Tantay or
Laurence Heilbronn, both of Image 7, +33-1-53-70-74-93, +33-1-53-70-74-64, for
Transgene
(TRGNY)
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Transgene has five products in clinical development, two of which are
in Phase II clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus.
Na ich freue mich schon auf die Reise nach Frankreich zur HV!
jàime la france!
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Wednesday May 12, 8:45 am ET
STRASBOURG, France, May 12 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced the scheduled presentations of data on two product candidates at the American Society of Clinical Oncology annual meeting, June 5-8, 2004 in New Orleans, Louisiana.
Mirjana Urozevic, MD, from the Department of Dermatology, University Hospital, Zurich, Switzerland, will present interim results of Transgene's Ad-IFN gamma product candidate currently in a Phase I/II clinical trial in primary cutaneous lymphoma. The Ad-IFN gamma abstract has been selected to receive a 2004 ASCO Foundation Merit Award.
Patrick Squiban, MD, Vice-President Medical and Regulatory Affairs of Transgene will present interim results on the MVA-Muc1-IL2 cancer vaccine currently in Phase II clinical trial for lung, prostate and kidney cancer.
Presentations:
Title:
"Phase I/II study of adenovirus-interferon gamma (TG 1042) in primary
cutaneous lymphomas (CL)"
Date and time of the session:
June 6, 2004 - 11:00 am to 12:00 pm
---------------------
Title:
"MVA-Muc1-IL2 vaccine immunotherapy for advanced non small cell lung cancer
(NSCLC): Interim Phase II Data"
Date and time of the session:
June 7, 2004 - 8:00 am to 12:00 pm
About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines, immunotherapy products, and delivery technologies for the treatment of diseases for which there is no cure or adequate treatment at present, with a focus on the treatment of cancer. Transgene has five products in clinical development, two of which are in Phase II clinical trials, two in Phase I/II and one that has completed Phase I clinical trial. Transgene's proprietary vector technology platform consists of adenovirus and poxvirus.
--------------------------------------------------
Source: Transgene
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Latest News
--------------------------------------------------
(Printer friendly version) Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual Meetings
STRASBOURG, France, Jun 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene
(Nasdaq: TRGNY; Euronext: FR0005175080) announced today the presentation of
updated interim results of ongoing Phase II clinical trials with its MVA-Muc1-
IL2 therapeutic cancer vaccine candidate in lung and prostate cancers. Data from
the ongoing phase II trial in lung cancer were presented on Monday, June 7 at
the 2004 American Society of Clinical Oncology (ASCO) Annual Meeting in New
Orleans, Louisiana. Data from the ongoing phase II trial in prostate cancer were
presented on June 4 at the 7th Annual Meeting of the American Society of Gene
Therapy (ASGT) in Minneapolis, Minnesota.
"We were very pleased to have the opportunity to present these results at such
renowned events as the ASGT and ASCO Annual Meetings," said Jean-Francois
Carmier, Chief Executive Officer of Transgene. "We are excited to share these
results with leaders in both the fields of cancer and gene therapy."
Non-small-cell lung cancer
The current phase II trial is evaluating the efficacy of subcutaneous injections
of MVA-Muc1-IL2 at a dose of 108 pfu in association with a
cisplatin/vinorelbine-based chemotherapy in patients with advanced or metastatic
non-small-cell lung cancer (stage IIIB or IV).
A classical two-stage design is being used to evaluate the tumor response rates
and assess whether the treatment has sufficient activity against the disease to
warrant further development. The statistical hypothesis reflecting the chosen
lower and upper target response rates to be reached (20 and 40 percent,
respectively) requires at least five responses out of 18 patients in the first
stage, in order to proceed to the second stage, and 11 responses out of 33
patients at the end of the second stage. Enrollment is now complete.
The following responses were observed in the first 18 patients who received
upfront the combination of MVA-Muc1-IL2 with chemotherapy and have been
evaluated for response (stage 1 of the study):
* seven patients have responded to the treatment according to the RECIST
criteria (partial responses, of which five have been validated to date
in central review); and
* five patients had their disease stabilized for more than twelve weeks.
Together, these results indicate that 12 out of 18 patients have benefited from
the combination of MVA-Muc1-IL2 vaccination with chemotherapy. In the sub-group
of metastatic disease (14 patients with stage IV), 11 patients (79%) showed
clinical benefit (partial and stable diseases). Results from the ongoing stage 2
of the study are expected in the coming months.
Prostate cancer
The prostate cancer trial is evaluating MVA-Muc1-IL2 in patients who have had
primary local treatment by surgery or radiation and subsequently had progressive
elevation of their PSA (Prostate Specific Antigen) level without documented
evidence of metastatic disease, which suggests residual or recurrent prostate
cancer. There is increasing interest, as suggested by various publications and
meetings, to propose new treatments at this stage of rising PSA.
The trial is taking place in the United States as a Phase II multi-center,
randomized, open label trial to assess the clinical and biological effects of
two different vaccination schedules. The patients in the first arm receive a
weekly 108 pfu injection of MVA-Muc1-IL2 for six weeks and thereafter every
three weeks. Patients in the second arm receive the same treatment every three
weeks.
To date, 30 patients have been included and PSA data is available for 29 of them
to allow calculation of the change in the PSA doubling-time (PSA-DT) induced by
the vaccination. PSA-DT increased three-fold in patients receiving the weekly
injections and almost two-fold in patients receiving the three-week schedule.
Using a model-based analysis of the patient population, these changes in the
PSA-DT are highly significant with p
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
STRASBOURG, France, Jul 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene
(Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced that it
manufactured clinical lots of HIV vaccine candidates in the frame of EUROVAC
(European Vaccine Effort against HIV/AIDS), a European cluster of 21
laboratories, funded since 2000 by the European Union under the 5th Framework
Programme.
Partners of EUROVAC, the Karolinska Institutet and Aventis Pasteur, recognizing
Transgene's know-how in the field of recombinant vaccines production, selected
the company to produce clinical lots of NYVAC-based vaccines carrying genes of
HIV-1. Production was completed in Transgene's manufacturing facility located
near Strasbourg, through adaptation of its own MVA manufacturing process to the
production of NYVAC-based products. NYVAC and MVA are both attenuated strains of
the vaccinia virus.
"We are very proud of the confidence put in us by the Karolinska Institutet,
EUROVAC and Aventis Pasteur for our manufacturing capabilities of recombinant
vaccines," stated Jean-Francois Carmier, Chief Executive Officer of Transgene.
"We believe manufacturing contracts add value to our expertise, while
contributing to reducing our burn rate."
About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated
to the discovery and development of therapeutic vaccines, immunotherapy
products, and delivery technologies for the treatment of diseases for which
there is no cure or adequate treatment at present, with a focus on the treatment
of cancer. Transgene has five products in clinical development, two of which are
in Phase II clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus.
This press release contains forward-looking statements, including statements
regarding Transgene manufacturing capabilities. Statements that are not
historical facts are based on Transgene's current expectations, beliefs,
estimates, forecasts and assumptions, including Transgene's expectations related
to the reproducibility in humans of the preclinical results, progress in the
clinical trials and Transgene's belief as to the potential to successfully
manufacture products for the effective treatment of illness. The statements
contained in this release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions which are difficult to predict.
Accordingly, actual outcomes and results may differ materially from what is
expressed in those forward-looking statements. Important factors which may
affect Transgene's future operating results include the following: Transgene's
product candidates may not demonstrate therapeutic efficacy after initial
promising results, Transgene may be unable to obtain regulatory approval for its
product candidates, Transgene may be unable to conduct its clinical trials as
quickly as it has predicted, Transgene's clinical trials may not produce results
sufficient to justify further product development, Transgene may not have
sufficient resources to complete the research, manufacturing and
commercialization of any of its product candidates, competitors may develop
technologies or products superior to Transgene's technologies or products,
Transgene may not be able to successfully enforce the intellectual property
rights in all jurisdictions relating to its product candidates and other
important factors described in Transgene's Annual Report on Form 20-F for the
year ended December 31, 2003 filed with the U.S. Securities and Exchange
Commission, including those factors described in the section entitled "Risk
Factors."
SOURCE Transgene
CONTACT: Michel Hubert, VP Business Development, Transgene,
+33-3-88-27-91-12; Michael Long, Cohn & Wolfe, +1-212-798-9775; Estelle
Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn, +33-1-53-70-74-64,
both of Image 7, for Transgene
(TRGNY)
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
TRANSGENE SA ADS - Nasdaq National Market: TRGNY
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004 |
STRASBOURG, France, Nov 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene(Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced cash position andnet cash expenditures for the third quarter and the nine months ended September30, 2004 (unaudited figures, USGAAP).Net cash expenditures amounted to euro 4.8 million (US$ 6.0 million) and euro14.9 million (US$ 18.5 million) for the third quarter and the first nine monthsof 2004, respectively. The net cash expenditures for the third quarter and thefirst nine months of 2003 amounted to euro 4.1 million (US$ 5.1 million) andeuro 13.8 million (US$ 17.1 million), respectively. The increase in net cashexpenditures in the first nine months of 2004 reflects a refund of research taxcredit of euro 0.2 million (US$ 0.2 million) in 2004 compared to euro 0.8million (US$ 1.0 million) in 2003 and a decrease of interest income due to lowercash held, cash outflows being unchanged.Cash and cash equivalents totaled euro 20.0 million (US$ 24.8 million) atSeptember 30, 2004. We believe that, based on our current estimates (coststructure, clinical development plans, operating revenues, capital expenditures... ), our cash position at September 30, 2004 will be sufficient to meet ourexpected financial requirements, including for our research and developmentactivities and our anticipated capital expenditures, through the end of July2005.Transgene also announced its decision to modify the content of its quarterlyfinancial communications. Because our research and development programs focus onthe mid- and long-term, we believe that the release of quarterly detailedfinancial results does not reflect this timing. As a result and as permitted byapplicable regulations and practices, we have decided to publish financial datafrom now on as follows: Fiscal year and half year results: consolidated balance sheet, statement of operations and net cash expenditures; First and third quarters: consolidated net cash expenditures and cash position.Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicatedto the discovery and development of therapeutic vaccines, immunotherapyproducts, and delivery technologies for the treatment of diseases for whichthere is no cure or adequate treatment at present, with a focus on the treatmentof cancer. Transgene has five products in clinical development, two of which arein Phase II clinical trials, two in Phase I/II and one that has completed PhaseI clinical trial. Transgene's proprietary vector technology platform consists ofadenovirus and poxvirus.This press release contains forward-looking statements regarding Transgene'sfinancial requirements and expenditures. These statements are based onTransgene's current expectations, beliefs, estimates, forecasts and assumptionsand are not guarantees of future performance. Accordingly, actual outcomes andresults may differ materially from what is expressed. Important factors whichmay affect Transgene's future financial requirements and expenditures includethe following: regulatory approvals for product development and testing may besuspended or delayed, causing additional expenses to continue testing or obtaintesting rights; proceedings to obtain patents and litigation of third partyinfringement claims are expensive and could exceed anticipated budgets; rightsto proprietary genes and other technologies to further develop our business maybe more costly than anticipated; we may incur significant costs in connectionwith our product liability exposure; we may incur unanticipated costs inconnection with our use and handling of hazardous material; and other importantfactors described in Transgene's Annual Report on Form 20-F for the most recentfiscal year filed with the U.S. Securities and Exchange Commission, includingthose factors described in the section entitled "Risk Factors."Note: The official financial information of Transgene is stated in Euros. Thefinancial information expressed in US$ is translated solely for the convenienceof the reader at euro 1.00 = $ 1.2417, the noon buying rate of the FederalReserve Bank of New York on September 30, 2004.SOURCE TransgeneCONTACT: Philippe Poncet, Chief Financial Officer of Transgene, +33-0-3-88-27-91-21; or Michael Long of Cohn & Wolfe, +1-212-798-9775; or Estelle Guillot-Tantay, +33-0-1-53-70-74-93 or Laurence Heilbronn, +33-0-1-53-70-74-64, both of Image 7URL: http://www.transgene.fr http://www.prnewswire.comCopyright (C) 2004 PR Newswire. All rights reserved.KEYWORD: FranceINDUSTRY KEYWORD: HEA MTC BIOSUBJECT CODE |
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical Lesions |
STRASBOURG, France, Nov 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene(Nasdaq: TRGNY; Euronext: FR0005175080) announced today that it is conducting anew Phase II clinical trial with its vaccine candidate MVA-HPV-IL2 in womendiagnosed with pre-cancerous lesions of the cervix (cervical intraepithelialneoplasia - CIN 2/3) related to type-16 human papillomavirus (HPV16). Based onthe favorable data obtained from the previous Phase II trial that was conductedon CIN 2/3, this newly approved trial will evaluate the efficacy of MVA-HPV-IL2after a 6-month observation period, which will give patients longer time tomount an immune response.The first Phase II trial included 31 patients with HPV16-related CIN 2/3, 29 ofwhich were evaluable for product efficacy. The patients were randomized into twosubgroups for the evaluation of two different doses (5.10(5) pfu and 5.10(7)pfu) of the vaccine candidate. Per the trial's protocol, the patients underwentsurgical removal of the lesions (conisation) six weeks after vaccination. Whileno indication of CIN 2/3 regression was shown in the patients treated with thelow dose of the vaccine, responses were documented after only six weeks in sevenout of 16 patients in the high dose group. Responses were measured in the formof lesion-grade or -size reduction through histology analysis (five patients)and/or viral clearance (four patients).The new trial is being conducted at six centers in France. Candidate enrollmentis on-going and preliminary data are expected during the second half of 2005. 18patients with HPV16-related CIN2/3 will receive three injections of thehigh-dose vaccine (5.10(7) pfu) administered sub- cutaneously. They will bemonitored every 2 months for 6 months with colposcopy, virology, cytology andpossibly histology controls. Only those still presenting with a CIN2/3 or an HPVinfection at the end of the 6-month period will undergo a conisation. The otherpatients will be considered as having responded to the therapeutic vaccinationand will not be considered to require conisation. They will continue to bemonitored to ensure that the regression is complete and long-lasting."Every year, 165,000 women in the U.S. and Europe are diagnosed withHPV16-related CIN 2/3," stated Dr. Patrick Squiban, Vice-President, Medical andRegulatory Affairs of Transgene. "We believe that an effective therapeuticvaccination against HPV16 constitutes a novel approach that may offer analternative to conisation in the future."About MVA-HPV-IL2 cancer vaccineTransgene's MVA-HPV-IL2 product candidate uses the MVA virus to carry andexpress two HPV antigens found in HPV 16, the E6 and E7 proteins. The newgeneration MVA vector is a highly attenuated poxvirus that combines theadvantages of a strain extensively tested in humans as a smallpox vaccine withthe ability to stimulate a strong immune response to antigens. The sequencecoding for the cytokine interleukin 2 (IL-2) is included to help stimulatespecific T cell responses.About TransgeneTransgene, based in Strasbourg, France, is a biopharmaceutical company dedicatedto the discovery and development of therapeutic vaccines, immunotherapyproducts, and delivery technologies for the treatment of diseases for whichthere is no cure or adequate treatment at present, with a focus on the treatmentof cancer. Transgene has five products in clinical development, two of which arein Phase II clinical trials, two in Phase I/II and one that has completed aPhase I clinical trial. Transgene's proprietary vector technology platformconsists of adenoviral and poxviral families.This press release contains forward-looking statements, including statementsregarding the efficacy and safety of and potential market for Transgene'sproduct candidates and prospects. Statements that are not historical facts arebased on Transgene's current expectations, beliefs, estimates, forecasts andassumptions, including Transgene's expectations related to progress in theclinical trials and Transgene's belief as to the potential of MVA-HPV-IL2 as atreatment against CIN 2/3 and HPV infection. The statements contained in thisrelease are not guarantees of future performance and involve certain risks,uncertainties and assumptions which are difficult to predict. Accordingly,actual outcomes and results may differ materially from what is expressed inthose forward-looking statements. Important factors which may affect Transgene'sfuture operating results include the following: Transgene may not havesufficient resources to complete on-going clinical trials and continue itsresearch and development activities after mid-2005, Transgene's productcandidates may not demonstrate therapeutic efficacy after initial promisingresults, Transgene may be unable to obtain regulatory approval for its productcandidates, Transgene may be unable to conduct its clinical trials as quickly asit has predicted, Transgene's clinical trials may not produce results sufficientto justify further product development, competitors may develop technologies orproducts superior to Transgene's technologies or products, Transgene may not beable to successfully enforce the intellectual property rights in alljurisdictions relating to its product candidates and other important factorsdescribed under "Risk Factors" and elsewhere in Transgene's Annual Report onForm 20-F for the year ended December 31, 2003 filed with, and in its Reports onForm 6-K furnished to, the U.S. Securities and Exchange Commission.SOURCE TransgeneCONTACT: Patrick Squiban of Transgene, VP, Medical & Regulatory Affairs, +33-3-88-27-91-73; or Michael Long of Cohn & Wolfe, +1-415-365-8523, for Transgene; or Estelle Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn, +33-1-53-70-74-64, both of Image 7, for Transgene (TRGNY)http://www.prnewswire.comCopyright (C) 2004 PR Newswire. All rights reserved.KEYWORD: FranceINDUSTRY KEYWORD: HEA BIO MTC |
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Optionen
Antwort einfügen |
Boardmail an "geldschneider" |
Wertpapier:
Transgene
|
0
Wird wohl nach Bitcoins und Brennstoffzellen der neue Hype: Biotechs. Bin gespannt :-)
Optionen
Antwort einfügen |
Boardmail an "Alibabagold" |
Wertpapier:
Transgene
|
0
Moderation
Zeitpunkt: 23.04.21 15:01
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Spam
Zeitpunkt: 23.04.21 15:01
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Spam
Optionen
Antwort einfügen |
Boardmail an "Sarahfuoka" |
Wertpapier:
Transgene
|